Literature DB >> 14624356

Time interval of measles vaccination in patients with Kawasaki disease treated with additional intravenous immune globulin.

Masaru Miura1, Yasuki Katada, Jun Ishihara.   

Abstract

UNLABELLED: A standard treatment with a dose of 2 g/kg of intravenous immune globulin (i.v.IG) is sometimes ineffective in some patients with Kawasaki disease (KD), who are commonly treated with additional i.v.IG. An interval of 6 to 7 months in Japan and 11 months in the United States is recommended before vaccination against measles after i.v.IG treatment for KD, but it is not known how long after treatment with additional i.v.IG. We studied the persistence of measles antibody titers in six episodes of KD in five patients without history of measles infection or vaccination, 4 to 28 months of age, after additional infusion of i.v.IG. The total dose was 4 g/kg in five episodes and 6 g/kg in one episode. Enzyme immunoassay antibody titers against measles were still positive (> or =400) in all patients tested 3 months after additional infusion of i.v.IG and positive in one patient and equivocal (> or =200 and <400) in three patients after 6 months, but negative (<200) in all after 9 months following infusion. Neutralization test antibody titers against measles were still positive (> or =1:4) in all patients 3 months after additional infusion of i.v.IG, but only one after 6 months, and negative (<1:4) in all after 9 months following infusion.
CONCLUSION: We suggest that an appropriate interval between infusion of 4 g/kg of intravenous immune globulin and measles vaccination be 9 months. The 11-month interval recommended in the United States for 2 g/kg may be longer than necessary.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624356     DOI: 10.1007/s00431-003-1335-3

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  13 in total

1.  Reduced passive measles immunity in infants of mothers who have not been exposed to measles outbreaks.

Authors:  M Ohsaki; H Tsutsumi; R Takeuchi; Y Kuniya; S Chiba
Journal:  Scand J Infect Dis       Date:  1999

2.  Prevalence of measles antibody among young adult healthcare workers in a cancer hospital: 1980s versus 1998-1999.

Authors:  Susan K Seo; Sharp F Malak; Suzanne Lim; Janet Eagan; Kent A Sepkowitz
Journal:  Infect Control Hosp Epidemiol       Date:  2002-05       Impact factor: 3.254

3.  Interference of immune globulin with measles and rubella immunization.

Authors:  G R Siber; B G Werner; N A Halsey; R Reid; J Almeido-Hill; S C Garrett; C Thompson; M Santosham
Journal:  J Pediatr       Date:  1993-02       Impact factor: 4.406

4.  Measles vaccine failures: lack of sustained measles-specific immunoglobulin G responses in revaccinated adolescents and young adults.

Authors:  M L Cohn; E D Robinson; M Faerber; D Thomas; S Geyer; S Peters; M Martin; A Martin; D Sobel; R Jones
Journal:  Pediatr Infect Dis J       Date:  1994-01       Impact factor: 2.129

5.  Recommended timing of routine measles immunization for children who have recently received immune globulin preparations. American Academy of Pediatrics Committee on Infectious Diseases.

Authors: 
Journal:  Pediatrics       Date:  1994-04       Impact factor: 7.124

6.  Kawasaki disease: a maturational defect in immune responsiveness.

Authors:  T W Kuijpers; A Wiegman; R A van Lier; M T Roos; P M Wertheim-van Dillen; S Pinedo; J Ottenkamp
Journal:  J Infect Dis       Date:  1999-12       Impact factor: 5.226

7.  Management and outcome of persistent or recurrent fever after initial intravenous gamma globulin therapy in acute Kawasaki disease.

Authors:  R K Han; E D Silverman; A Newman; B W McCrindle
Journal:  Arch Pediatr Adolesc Med       Date:  2000-07

8.  A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome.

Authors:  J W Newburger; M Takahashi; A S Beiser; J C Burns; J Bastian; K J Chung; S D Colan; C E Duffy; D R Fulton; M P Glode
Journal:  N Engl J Med       Date:  1991-06-06       Impact factor: 91.245

9.  Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease.

Authors:  Kumi Yasukawa; Masaru Terai; Stanford T Shulman; Tetsuya Toyozaki; Shigehiro Yajima; Yoichi Kohno; Anne H Rowley
Journal:  Circulation       Date:  2002-02-12       Impact factor: 29.690

10.  Impact of revaccinating children who initially received measles vaccine before 10 months of age.

Authors:  H C Stetler; W A Orenstein; R H Bernier; K L Herrmann; B Sirotkin; D Hopfensperger; R Schuh; P Albrecht; A W Lievens; P A Brunell
Journal:  Pediatrics       Date:  1986-04       Impact factor: 7.124

View more
  3 in total

1.  Kawasaki syndrome: an intriguing disease with numerous unsolved dilemmas.

Authors:  Fernanda Falcini; Serena Capannini; Donato Rigante
Journal:  Pediatr Rheumatol Online J       Date:  2011-07-20       Impact factor: 3.054

2.  Lower CMV and EBV Exposure in Children With Kawasaki Disease Suggests an Under-Challenged Immune System.

Authors:  Diana van Stijn-Bringas Dimitriades; Annemarie Slegers; Hans Zaaijer; Taco Kuijpers
Journal:  Front Pediatr       Date:  2021-01-21       Impact factor: 3.418

3.  Response to Measles, Mumps and Rubella (MMR) Vaccine in Transfusion-Dependent Patients.

Authors:  Maddalena Casale; Nicoletta Di Maio; Valentina Verde; Saverio Scianguetta; Maria Grazia Di Girolamo; Rita Tomeo; Domenico Roberti; Saverio Misso; Silverio Perrotta
Journal:  Vaccines (Basel)       Date:  2021-05-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.